Many senior academic staff also work as honorary consultants for the trust in clinical services such as the National Psychosis Unit at Bethlem Royal Hospital.

It was part of the original plans of Frederick Mott and Henry Maudsley—inspired by the Munich institute of Emil Kraepelin—that the hospital would include facilities for teaching and research in 1896.

[4] In 1914, London County Council agreed to establish a hospital in Denmark Hill and Mott's plan began to take shape.

The department holds particular expertise in multivariate statistical methods for measurement, life-course epidemiology and the analysis of experimental, genetic and neuropsychiatric data.

The department is dedicated to the study of developmental disorders such as ADHD, clinical depression, autism and learning difficulties.

The Department of Clinical Neuroscience in Windsor Walk also contains the MRC London Neurodegenerative Disease Brain Bank.

It includes the King's Centre for Military Health Research, led by the department's former chair, Professor Sir Simon Wessely, and is responsible for studying the psychological impacts of the 2003 Iraq War.

The department also contains a programme of work on liaison psychiatry and studies the many complex interactions between mental and physical illness.

Research at the SGDP acknowledges that there is no simple solution to the "nature versus nurture" debate; instead, expertise is combined across fields such as social epidemiology, child and adult psychiatry, developmental psychopathology, development in the family, personality traits, cognitive abilities, statistical genetics, and molecular genetics.

In this way it is hoped that a greater understanding can be achieved in risk factors that might predispose an individual to depression, ADHD, or autism.

The MRC and the institute found that there was a need for refocusing and reintegration with other strands of research including psychiatric genetics and disorders of adult life.

[8] Rutter and David Goldberg discussed with the MRC about the establishment of an interdisciplinary research centre that could comprehensively study the interplay of nature and nurture in the development of psychiatric disorders.

Work focuses on integrating cognitive measures and multimodal neuroimaging techniques, with perinatal, genetic and developmental data.

The section has initiated or participated a number of such treatment studies of new atypical antipsychotics and potential mood stabilising medication and is also developing computerised and web-based applications for disease self-management.

[12] Sources include the government's National Institute for Health and Care Research (NIHR) and Higher Education Funding Council for England, grant-giving bodies such as the Medical Research Council (UK) and the Wellcome Trust, as well as other governmental, charitable and private-sector organisations.

[13] The IoPPN and the pharmaceutical company Lundbeck are led one of the largest ever academic-industry collaborations in research, known as NEWMEDS - Novel Methods leading to New Medications in Depression and Schizophrenia.

NEWMEDS aims to facilitate the development of new psychiatric medications by bringing top scientists and academics together in partnership with nearly every major global drug company.

[14] Another key project is the KCL and Janssen led pre competitive public private consortium RADAR-CNS[15] (Remote Measurement of Disease and Relapse in Central Nervous System Disorders), which uses smartphones and wearable devices to track clinical outcomes in disorders like depression, multiple sclerosis and epilepsy.